Shares of Guardant Health Inc. (GH) are soaring in Monday's intraday trading, registering a significant 5.02% increase. The surge comes as investors react positively to a recent analyst report.
Piper Sandler, a prominent financial services firm, has maintained its Buy rating on Guardant Health stock. In a report released earlier today, analyst David Westenberg reiterated the firm's bullish stance on the company, setting a price target of $60.00. This vote of confidence from a respected Wall Street firm appears to be driving the stock's upward momentum.
Guardant Health, known for its innovative liquid biopsy tests for cancer, has been attracting attention in the healthcare sector. The reaffirmation of the Buy rating suggests that Piper Sandler sees potential for further growth and value creation in the company. As investors digest this information, the stock's performance today indicates a positive market response to the analyst's outlook.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.